A Review of our Projects, Publications, and Discoveries
We studied the effect of ethyl pyruvate (EP), the ethyl ester of pyruvic acid, on the malignant phenotype of MM cells in tissue culture and on tumor growth in vivo using an orthotopic MM xenograft model.
Online journal: Expert Review of Respiratory Medicine
Malignant mesothelioma is an aggressive cancer whose pathogenesis is causally linked to occupational exposure to asbestos. Familial clusters of mesotheliomas have been observed in settings of genetic predisposition. Mesothelioma incidence is anticipated to increase worldwide in the next two decades. Novel treatments are needed, as current treatment modalities may improve the quality of life, but have shown modest effects in improving overall survival. Increasing knowledge on the molecular characteristics of mesothelioma has led to the development of novel potential therapeutic strategies, including: molecular targeted approaches, that is the inhibition of vascular endothelial growth factor with bevacizumab; immunotherapy with chimeric monoclonal antibody, immunotoxin, antibody drug conjugate, vaccine and viruses; inhibition of asbestos-induced inflammation, that is aspirin inhibition of HMGB1 activity may decrease or delay mesothelioma onset and/or growth. We elaborate on the rationale behind new therapeutic strategies, and summarize available preclinical and clinical results, as well as efforts still ongoing.
Authors: Angela Bononi, Andrea Napolitano, Harvey I Pass, Haining Yang, and Michele Carbone
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression
Aspirin (acetylsalicylic acid, ASA) is the most widely used nonsteriodial anti-inflammatory drug that reduces the incidence, metastatic potential and mortality of many inflammation-induced cancers. Can it play a role in helping patients with malignant mesothelioma?